ArticleJournal of hematology & oncology2026
Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting.
Article in Journal of hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Advances in targeted therapies for newly diagnosed primary central nervous system lymphoma (PCNSL) were a key highlight at the 2025 ASH Annual Meeting. While high-dose methotrexate (HD-MTX) remains the cornerstone of PCNSL treatment, the integration of BTK inhibitors, immunomodulators, and novel agents-such as selinexor and anti-PD-1 antibodies-is reshaping the first-line management paradigm. These emerging combinations are improving response rates and survival, paving the way for more effective strategies. Here, we provide a timely synthesis of these pivotal updates presented at ASH 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.